Moreover, a meta-analysis of 46 case–control studies indicated that CYP1A2*1F polymorphism was associated with estrogen-related breast and ovarian cancer risk, but not lung, colorectal, bladder, endometrial, pancreatic and gastric cancer [13]. The gene discussed is CYP1A2; the disease is gastric cancer.